|
Match
|
Document |
Document Title |
|
|
US20090298881 |
Water-Soluble Artemisinin Derivatives, Their Preparation Methods, the Pharmaceutical Compositions and the Use Thereof
Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions containing the same derivatives and the use thereof are disclosed. The artemisinin derivatives have...
|
|
|
US20090298880 |
METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods...
|
|
|
US20090298833 |
PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and...
|
|
|
US20090298783 |
Cosmetic Compositions
Disclosed is a method for preventing and/or soothing dry or sensitive skin against external stresses, comprising contacting the skin with a composition including an agent that decreases the release...
|
|
|
US20090275615 |
Method of treating thermoregulatory disfunction with paroxetine
The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally...
|
|
|
US20090264459 |
Organic Compounds
Compounds of formula (I) in free or a pharmaceutically acceptable salt form, wherein X 1 , L and Q have the meanings as indicated in the specification, are useful for treating obstructive or...
|
|
|
US20090264405 |
Cetp Inhibitors
Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or...
|
|
|
US20090258901 |
LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF
One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian...
|
|
|
US20090253684 |
LEUKOTRIENE B4 INHIBITORS
Provided herein are compounds of the formula (I):
as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and...
|
|
|
US20090247583 |
PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND PAROXETINE
A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from...
|
|
|
US20090247509 |
Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating...
|
|
|
US20090239908 |
METHODS OF TREATING PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE CNTF GENE
This invention relates to the use of the association between the 103 G>A polymorphism in the CNTF gene to determine antipsychotic treatment strategies in patients with psychotic disorders.
|
|
|
US20090209583 |
2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS
The present invention relates to 2-(substituted-amino)-benzothiazole sulfonamide compounds and derivatives, their use as protease inhibitors, in particular as broad-spectrum HIV protease...
|
|
|
US20090203714 |
Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors
The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof,
wherein:
X is CH or N; and R 4 is optionally substituted C 3-8 alkyl or optionally...
|
|
|
US20090192194 |
Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them
A compound of formula (I)
wherein R is a radical selected from
in which R 7 is halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; p is an...
|
|
|
US20090192170 |
Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors
The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof (I), wherein: R 3 is cyclopentyl or cyclohexyl; X is CH or N; and R 4 is optionally...
|
|
|
US20090186906 |
Furo[3, 2-b] pyrrol derivatives
The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: R 3 is ten-butylmethyl, sec-butyl or tert-butyl; X is CH or N; and R 4 is...
|
|
|
US20090182011 |
Chimeric Nitrate Esters and Use of the Same in a Treatment for Depression
Chimeric nitrate esters and their use in the treatment of depression are disclosed. The chimeric nitrate esters also are useful in the treatment of depression and comorbidity associated with aging.
|
|
|
US20090176739 |
OPTICAL ISOMERS OF AN ILOPERIDONE METABOLITE
The present invention relates to novel isomers of a metabolite of Iloperidone, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
|
|
|
US20090170899 |
Stimulators of 5-HT4 receptors and uses thereof
The present invention relates to a novel combination of a serotonin selective re-uptake inhibitor (SSRI) and an agonist of the serotonin 4 (5-HT 4 ) receptor to augment and/or provide faster onset...
|
|
|
US20090170843 |
(Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents
The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their...
|
|
|
US20090169616 |
FORMULATION AND METHOD FOR THE RELEASE OF PAROXETINE IN THE LARGE INTESTINE
The present invention provides a delayed and/or controlled release formulation of paroxetine or a pharmaceutically acceptable salt thereof that is formulated to release a substantial portion of the...
|
|
|
US20090163517 |
BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES
This invention is concerned with compounds of the formula
wherein X, A, B, R 1 , R 2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The...
|
|
|
US20090163485 |
HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
The present invention relates to compounds of formula
wherein
Ar, Het, R 1 and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers,...
|
|
|
US20090163451 |
METHODS FOR TREATING VISCERAL PAIN
The invention features methods of treating visceral pain in humans by administering an effective amount of a 5HT 1B or 5HT 1D receptor agonist, (e.g., a triptan). These methods can be used, for...
|
|
|
US20090156592 |
Fungicidal Azocyclic Amides
Disclosed are compounds of Formulae 1, 1A, 1B and 1C including all geometric and stereoisomers, N-oxides, and salts thereof,
wherein
R 1 , R 2 , R 4a1 , R 4a2 , A, A a , G, M, W, Z 1 , Z...
|
|
|
US20090143433 |
COCKTAIL FOR MODULATION OF ALZHEIMER'S DISEASE
Formulations for the prevention and treatment of neurological diseases and cognitive deficiencies, i.e., Alzheimer's Disease (AD), Parkinson's Disease, amyotrophic lateral sclerosis, mild cognitive...
|
|
|
US20090143432 |
Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.
|
|
|
US20090143353 |
ANTIFUNGAL BICYCLIC HETERO RING COMPOUNDS
A 1,6-β-glucan synthetase inhibitor is provided, having potent growth inhibition and having excellent safety. A compound is provided, capable of expressing in a wide spectral range and...
|
|
|
US20090137629 |
Sigma receptor binding agent containing indanone derivative
A method for treatment of a mental disorder containing the step of administering a therapeutically effective amount of a sigma receptor binding agent containing an indanone compound represented by...
|
|
|
US20090137566 |
Substituted Piperdines as Renin Inhibitors
The invention relates to substituted 3,4- or higher substituted piperididine compounds, the use thereof for the preparation of a pharmaceutical formulation for the treatment of a disease that...
|
|
|
US20090130077 |
SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS
The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for...
|
|
|
US20090124592 |
PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY
This invention relates to the use of a ligand of the 5-HT 4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT 4 receptor or of a...
|
|
|
US20090118267 |
INDANES
Compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , and q have the meanings indicated in claim 1 , can be employed, inter alia, for the treatment of tumours.
|
|
|
US20090075974 |
AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS
Disclosed is a pharmaceutical composition for prophylaxis and treatment of pancreatitis comprising a 5-HT2A receptor antagonist as an effective component, wherein the binding activity (pKi) of the...
|
|
|
US20090068290 |
BIFEPRUNOX DOSES FOR TREATING SCHIZOPHRENIA
The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but...
|
|
|
US20090062261 |
NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP
It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist. A...
|
|
|
US20090062259 |
Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists
The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a...
|
|
|
US20090054403 |
Treatment of Post-Traumatic Stress Disorder
Provided are methods of treating a patient diagnosed with post-traumatic stress disorder, by administering to the patient a therapeutically effective amount of Compound A. Also provided are methods...
|
|
|
US20090048229 |
Methods for promoting wakefulness
The present invention relates to methods of promoting wakefulness in an individual by administering a carbamoyl ester or a pharmaceutically acceptable salt thereof.
|
|
|
US20090047234 |
Compositions for nasal delivery
The present invention concerns a method of administering at least one active pharmaceutical agent to a patient in need thereof, which method comprises the intranasal administration of a composition...
|
|
|
US20090042854 |
Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists
The present invention is directed to certain hexahydrpyrrolidinone compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance...
|
|
|
US20090036488 |
RECURRENCE PREVENTIVE THERAPEUTIC AGENT FOR PSYCHOSTIMULANT-INDUCED PSYCHOSIS AND SCHIZOPHRENIA
The present invention provides a therapeutic agent for preventing recurrence of psychostimulant-induced psychosis and schizophrenia. This therapeutic agent for preventing recurrence of...
|
|
|
US20090036444 |
5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
The present invention relates to a fused ring compound represented by the following formula [I]
wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt...
|
|
|
US20090029977 |
DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS
The present invention relates to compounds of the formula (I)
wherein R 1 , R 2 , X and n are as defined in the specification as dual modulators of the serotonin 5-HT 2a and dopamine D 3 ...
|
|
|
US20090023779 |
Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents
The present invention relates to compounds of formula (I):
in which R 1 , R 2 , R 3 , X, Y and A are as defined in the specification. The compounds are modulators of the estrogen receptors.
|
|
|
US20090012055 |
Organic compounds
Novel substituted piperidines of the general formulae (I) and (II)
with the substituent definitions as explained in detail in the description are described. The compounds are suitable in...
|
|
|
US20090005309 |
SUBSTITUTED PIPERIDINES
Disclosed herein are substituted piperidine-based muscarinic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
|
|
|
US20090004308 |
USE OF ORGANIC ACIDS AND ESSENTIAL OILS IN ANIMAL FEEDING
The present invention relates to a novel feed composition for animals, for example poultry, comprising as active ingredient benzoic acid, derivatives or metabolites thereof, in combination with a...
|
|
|
US20080317883 |
METHODS FOR TREATING DEPRESSION
The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more carbamate compounds of...
|